#VolitionRx #Nu.Q® Cancer #Hospices Civils de Lyon

VolitionRx Takes Bold Steps Towards Reimbursement for Cancer Assays

In an exciting development for cancer diagnostics, VolitionRx Limited (NYSE AMERICAN: VNRX), an innovative multinational epigenetics firm, has announced its plans for a reimbursement submission concerning its groundbreaking Nu.Q® Cancer assays. This forward-thinking initiative is set to unfold in France, with vital backing from the Hospices Civils de Lyon (HCL), the nation's second-largest university hospital network.

The impending submission highlights Volition's commitment to enhancing cancer management practices, particularly for lung cancer patients. The collaboration with HCL is noteworthy; it brings together Volition's advanced technologies and HCL's extensive resources and clinical expertise. According to Professor Léa Payen, a Toxicology and Biochemistry expert from Claude Bernard University and HCL, the aim is to integrate the Nu.Q® assays into standard clinical practice across the hospital system as swiftly as possible, ideally later this year.

Professor Payen emphasized the significance of the Nu.Q® test for enhancing the precision in lung cancer management, stating, "Our results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q® test can provide valuable insights concerning patient survival and progression-free survival." This endorsement highlights the scientific validation and clinical relevance of the Nu.Q® technology in managing lung cancer.

A Significant Market Opportunity

With around 50,000 new lung cancer diagnoses annually in France, as noted by Volition, the potential impact of introducing the Nu.Q® assay into routine clinical use is substantial. The company's Vice President of Global Products, Frederic Wuilque, indicated that the reimbursement submission under the